Which atypical antipsychotic may be used for bipolar depression and carries a risk for QT prolongation?

Ziprasidone is an atypical antipsychotic that is indicated for the treatment of bipolar disorder, particularly for bipolar depression. One of the significant clinical considerations with ziprasidone is its potential to cause QT prolongation, which is a change in the heart's electrical activity that can lead to serious cardiac issues, including arrhythmias. This risk is particularly important to monitor, especially in patients who may already have cardiac risk factors or are on other medications that could exacerbate this effect.

In the context of its antipsychotic properties, ziprasidone has unique pharmacological profiles that make it a viable option for treating mood episodes in bipolar disorder, including depressive episodes. The ability to manage depressive symptoms while being aware of the cardiac implications is crucial for clinical decision-making in managing patients with bipolar disorder.